Alembic Pharmaceuticals shares jump after Q2 profit and US sales rise
In short
Alembic Pharmaceuticals reported Q2 results, and its US formulations revenue rose 77% to ₹1,003 crore. The company also launched three products in the US market during the quarter.
The update helped the shares rise. The report does not give the full profit number or say more about why sales grew.
What the reporting says
Alembic Pharmaceuticals posted Q2 results, with its US formulations business revenue rising 77% to ₹1,003 crore and three products launched in the US market during the quarter. The company’s share price jumped after the update, according to the publisher summary. The report does not state the full profit figure or explain what drove the higher US sales beyond the new launches.
Why it matters
Alembic Pharmaceuticals reported quarterly results with a strong rise in its US formulations business, which reached ₹1,003 crore after growing 77% in the quarter. The company also launched three products in the US market. The market reacted positively, with shares jumping after the update. The source does not provide the full net profit figure or other details on margins or guidance.